Gene Editing Multivalent messenger ribonucleic acid-lipid nanoparticle vaccines against SARS-CoV-2 Posted on May 3, 2022 by Editorial Staff A new study analyzed multivalent messenger ribonucleic acid (mRNA)-lipid nanoparticle (LNP) vaccine constructs against certain β-coronaviruses (β-CoVs). Share on FacebookTweetFollow us Editorial Staff Needle- and adjuvant-free vaccination with non-infectious T4-COVID nanoparticles induces strong immunity in mice New technology offers fighting chance against grapevine killer